NCT07899905
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24.
Timeframe: Baseline and Week 24
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 37 weeks.
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 21 weeks.
Secondary (3)
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
Percentage of Participants with Improvement in World Health Organization (WHO) Functional Class (FC) at Week 24
Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) at Week 24
Arms and interventions
SotaterceptExperimental
Sotatercept will be administered subcutaneous (SC) starting at a dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks (Q3W) plus background Pulmonary Arterial Hypertension (PAH) therapy.
Biologicals: Sotatercept